Members Login
Medical NewsEPG Search
Frequent Searches:
Browse Other Languages
Spanish Drug Data (España)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
YouTube - Featured Content
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Are you a Doctor or Healthcare Professional? Authorise Viewing
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Change language
Current language database:
United Kingdom
Medicine information : EASYHALER
| Drug class description : | Glucocorticoids |
| Generic Name : | Budesonide |
| Drug description : | Inhalation Powder. White or almost white powder. |
| Presentation : | Easyhaler® Budesonide 100 micrograms per actuation Inhalation Powder - One metered dose contains 100 micrograms of budesonide. With the Easyhaler device the delivered dose (ex-actuator) contains the same quantity of active substance as the metered dose (ex-reservoir). Easyhaler® Budesonide 200 micrograms per actuation Inhalation Powder - One metered dose contains 200 micrograms of budesonide. With the Easyhaler device the delivered dose (ex-actuator) contains the same quantity of active substance as the metered dose (ex-reservoir). Easyhaler® Budesonide 400 micrograms per actuation Inhalation Powder - One metered dose contains 400 micrograms of budesonide. With the Easyhaler device the delivered dose (ex-actuator) contains the same quantity of active substance as the metered dose (ex-reservoir). |
| Indications : | Treatment of mild, moderate and severe persistent asthma. |
| Adult Dosage : | Method of administration: For inhalation use. For optimum response, Easyhaler Budesonide Inhalation Powder should be used regularly. The therapeutic effect beging after a few days treatment and reaches its maximum after some weeks of treatment. When transferring a patient to Easyhaler Budesonide Inhalation Powder from other inhalation devices, the treatment should be individualised. The previou active substance, dose regimen and method of delivery should be considered. The patients should be prescribed a starting dose of inhaled budesonide which is appropriate for the severity or level of control of their disease. The starting dose for adults (including the elderly and children/adolescents over 12 years of age ) with mild asthma (Step 2) and for children 6 to 12 years of age is 200-400 micrograms / day. If needed, the dose can be increased up to 800 micrograms/day. If needed, the dose can be increased up to 88 micrograms/day. For adult patients with moderate (Step 3) and severe (Step 4) asthma the starting dose can be up to 1600 micrograms/day. The maintenance dose should be adjusted to meet the requirements of an individual patient taking into account the severity of the disease and the clinical response of the patient. The dose should be adjusted until control is achieved and then titrated to the lowest dose at which effective control of asthma is maintained. Twice daily dosing Adults with mild, moderate or severe asthma (including the elderly and children/adolescents over 12 years of age): The usual maintenance dose is 100-400 micrograms twice daily. During periods of severe asthma, the daily dose may be increased up to 1600 micrograms administered in divided (two) doses and subsequently reduced when asthma has stabilised. Children 6 to 12 years: The usual maintenance dose is 100-200 micrograms twice daily. If needed, the daily dose may be increased up to 800 micrograms administered in divided (two) doses and subsequently reduced when asthma has stabilised. Once daily dosing Adults with mild to moderate asthma (including the elderly and children/adolescents over 12 years of age): In patients who have not previously received inhaled corticosteroids the usual maintenance dose is 200-400 micrograms once daily. In patients already controlled on inhaled corticosteroids (eg budesonide or beclometasone dipropionate) administered twice daily, once daily dosing up to 800 micrograms may be used. The patient should be transferred to once daily dosing at the same equivalent total daily dose (with consideration of the drug and the method of delivery). The dose should be subsequently reduced to the minimum needed to maintain good asthma control. Patients should be instructed to take the once daily dose in the evening. It is important that the dose is taken consistently and at the same time each evening. There are insufficient data to make recommendations for the transfer of patients from newer inhaled corticosteroids to once daily Easyhaler Budesonide Inhalation Powder. Patients, in particular those receiving once daily treatment, should be advised that if their asthma deteriorates (e.g. increased frequency of bronchodilator use or persistent respiratory symptoms) they should double their corticosteroid dose by administering twice daily. They should be advised to contact their doctor as soon as possible. A rapid-acting inhaled bronchodilator should be available for the relief of acute symptoms of asthma at all times. Instructions for use and handling: Easyhaler is an inspiratory flow-driven device. This means that when the patient inhales through the mouthpiece, the substance will follow the inspired air into the airways. Note: It is important to instruct the patient • To carefully read yhe instructions for use in the patient information leaflet which is packed together with each inhaler. • That it is recommended to keep the device in the protective cover after opening the laminate pouch to enhance the stability of the product during use and make the inhaler more tamper proof. • To shake and actuate the device prior to each inhalation. • To breath in forcefully through the mouthpiece to ensure that an optimal dose is delivered to the lungs. • Never to breathe out through the mouthpiece as this will result in a reduction in the delivered dose. Should this happen the patient is instructed to tap the mouthpiece onto a table top or the palm of a hand to empty the powder, and then to repeat the dosing procedure. • Never to actuate the device more than once without inhalation of the powder. Should this happen the patient is instructed to tap the mouthpiece onto a table top or the palm of a hand to empty the powder, and then to repeat the dosing procedure. • To always replace the dust cap and close the protective cover after use to prevent accidental actuation of the device (which could result in either overdosing or underdosing the patient when subsequently used). • To rinse the mouth out withwater or brush the teeth after inhaling the prescribed dose to minimise the risk of oropharyngeal candidiasis and hoarseness. • To clean the mouthpiece with a dry cloth at regular intervals. Water should never be used for cleaning because the powder is sensitive to moisture. • To replace Easyhaler Budesonide Inhalation Powder when the counter reaches zero even though powder can still be observed within the device. |
| Child Dosage : | Children 6 to 12 with mild asthma: In steroid naïve patients or patients controlled on inhaled corticosteroids (eg budesonide or beclometasone dipropionate) administered twice daily the usual maintenance dose is 200-400 micrograms once daily. |
| Contra Indications : | Hypersensitivity to budesonide or to lactose. |
| Special Precautions : | Easyhaler Budesonide Inhalation Powder is not indicated for the treatment of acute dyspnoea or status asthmaticus. These conditions should be treated in the normal way. Patients should be aware that Easyhaler Budesonide Inhalation Powder is prophylactic therapy and therefore has to be used regularly even when asymptomatic benefit and shouls not be stopped abruptly. The transfer of patients treated with oral corticosteroid and their subsequent management requires special care. The patients should be in a reasonably stable state before initiating a high dose of inhaled corticosteroid through twice daily dosing in addition to their usual maintenance dose of systemic corticosteroid. After about 10 days, withdrawal of the systemic corticosteroid is started by reducing the daily dose gradually (by for example 2.5 milligrams prenisolone or the equivalent each month) to the lowest possible level. It may be possible to completely replace the oral corticosteroid with inhaled corticosteroid. Transferred patients whose adrenocortical function is impaired may need supplementary systemic corticosteroid during periods of stress e.g. surgery, infection or worsening asthma attacks. This applies also to patients who have received prolonged treatment with high doses of inhaled corticosteroids. They may also have impaired adrenocortical function which may result in clinically significant adrenal suppression and may need systemic corticosteroid cover during periods of stress. During transfer from oral inhaled budesonide symptoms may appear that had previously been suppressed by systemic treatment with glucocorticosteroids, for example symptoms of allergic rhinitis, eczema, muscle and joint pain. Specific treatment should be co-administered to treat these conditions. Some patients may feel unwell in a non-specific way during the withdrawal of systemic corticosteroids despite maintenance or even improvement in respiratory function. Such patients should be encouraged to continue treatment with inhaled budesonide and withdrawal of oral corticosteroid unless there are clinical signs to indicate the contrary, for example signs which might indicate adrenal insufficiency. As with other inhalation therapies paradoxical bronchospasm may occur manifest by an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway. Budesonide should be discontinued immediately, the patient should be assessed and, if necessary, alternative treatment instituted. When despite a well monitored treatment, an acute episode of dyspnoea occurs, a rapid-acting inhaled bronchodilator should be used and medical reassessment should be considered. If despite maximum doses of inhaled corticosteroids asthma symptoms are not adequately controlled, patients may require short-term treatment with systemic corticosteroids. In such a case, it is necessary to maintain the inhaled corticosteroid therapy in association with treatment by the systemic route. Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. It is important, therefore, that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained. It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist. Patients who have previously been dependent on oral corticosteroids may, as a result of prolonged systemic corticosteroid therapy, experience effects of impaired adrenal function. Recovery may take a considerable amount of time after cessation of oral corticosteroid therapy and hence oral steroid-dependent patients transferred to budesonide may remain at risk from impaired adrenocortical function for some considerable time. In such circumstances hypothalamic adrenocortical (HPA) axis function should be monitored regularly. To reduce the risk of oral candidasis and hoarsness patients should be advised to rinse out the mouth properly or brush the teeth after each administration of inhaled corticosteroid. Oral candidasis can be rapidly controlled by local antimycotic treatment, without the need to discontinue the treatment with inhaled budesonide. Exacerbation of clinical symptoms of asthma may be due to acute respiratory tract bacterial infections and treatment with appropriate antibiotics may be required. Such patients may need to increase the dose of inhaled budesonide and a short course of oral corticosteroids may be required. A rapid-acting inhaled bronchodilator should be used as “rescue” medication to relieveacute asthma symptoms. Special care and adequate specific therapeutic control of patients with active and quiescent pulmonary tuberculosis is necessary before commencing treatment with Easyhaler Budesonide Inhalation Powder. Similarly patients with fungal, viral or other functions of the airways require close observation and special care and should use Easyhaler Budesonide Inhalation Powder only if they are also receiving adequate treatment for such infections. In patients with excessive mucous secretion in the respiratory tract, short-term therapy with oral corticosteroids may be necessary. In patients with severe hepatic dysfunction, treatment with inhaled budesonide can result in a reduced elimination rate and hence enhanced systemic availability. Possible systemic effects may then result and therefore HPA axis function in these patients should be monitored at regular intervals. Concomitant treatment with ketoconazole or other potent CYP3A4 inhibitors should be avoided (See Interactions). If this is not possible the time interval administration of the interacting drugs should be as long as possible. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorbtion should not take this medicine. |
| Interactions : | Ketoconazole 200mg once daily increased plasma levels of concomitantly administered oral budesonide (single dose of 3mg) on average six-fold. When ketoconazole was administered 12 hours after the concentration was on average increased three-fold. Information about this interaction is lacking for inhaled budesonide, but marked increases in plasma levels could be expected. Since data to give dosage recommendations are lacking, the combination should be avoided. If this is not possible the time interval between administration of ketoconazole and budesonide should be as long as possible. A reduction in the dose of budesonide should also be considered. Other potent inhibitors of CYP3A4 are also likely to markedly increase plasma levels of budesonide. Pregnancy and lactation Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies glucocorticosteroids have been shown to induce malformations. This is not likely to be relevant for humans given recommended doses. Animal studies have also identified an involvement of excess prenatal glucocorticoids in increased risk for intrauterine, adult cardiovascular disease and permanent changes in glucocorticoid receptor density, neurotransmitter turnover and behaviour at exposures below the teratogenic dose range. During pregnancy, inhaled budesonide should only be used when the benefits outweigh the potential risk. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used. It is not known whether budesonide passes into human breast milk. Administration of inhaled budesonide to women who are breastfeeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child. |
| Adverse Reactions : | Frequency of reported adverse reactions: Common >1/100, <1/10) Respiratory system disorders: hoarseness, cough and throat irritation. Resistance mechanism disorders: oropharyngeal candidasis. Gastrointestinal disorders: difficulty in swallowing. Rare >1/10,000, <1/1000) Skin and appendages disorders: easy bruising, skin thinning, urticaria, rash, dermatitis, pruritus, erythema. Psychiatric disorders: depression, aggressive reactions, irritability, anxiety, psychosis, behavioural changes in children, restlessness, increased motorial activity. Endocrine disorders: hypocorticism, hypercorticism. Respiratory system disorders: bronchospasm (See Special Precautions). Body as a whole – general disorders: anaphylactic shock, angioedema, immediate and delayed hypersensitivity reactions. Musculoskeletal, connective tissue and bone disorders: growth retardation. Very rare including isolated cases (<1/10,000) Psychiatric disorders: nervousness. Endocrine disorders: adrenal suppression. Eye disorders: cataract, glaucoma. Musculoskeletal, connective tissue and bone disorder: decreased bone density. Theatment with inhaled budesonide may result in candida infection in the oropharynx. Experience has shown that candida infection occurs less often when inhalation is performed before meals and/or when the mouth is rinsed after inhalation. In most cases this condition responds to topical anfi-fungal therapy without discontinuing treatment with inhaled budesonide. Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These may include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma, and susceptibility to infections. The ability to adapt to stress may be impaired. The systemic effects described, however, are much less likely to occur with inhaled budesonide than with oral corticosteroids. |
| Manufacturer : | Ranbaxy |
| Drug Availability : | (POM) |
Free registration to access disease diagnosis, patient management, physician tools.
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org